Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro
- PMID: 3149257
- DOI: 10.1111/j.1472-8206.1988.tb00652.x
Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro
Abstract
Thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator (t-PA) from melanoma cells (mt-PA), recombinant t-PA (rt-PA), streptokinase (SK), single-chain urokinase plasminogen activator (scu-PA), and high and low molecular weight urokinase (HMW UK, LMW UK) were compared in vitro by means of systems using human plasma. Thrombolytic activities were tested on standard or labeled hanging clots. When compared on the basis of urokinase international units, t-PA appeared to be slightly more active than scu-PA and streptokinase, and about 10-fold more active than both preparations of UK when they were diluted in plasma. Fibrinolytic activity was evaluated by measuring the lysis time of recalcified plasma containing variable amounts of thrombolytic agents. t-PA was shown to be twice as active as HMW UK, which was itself more active than LMW UK. When scu-PA and both types of UK were compared on bovine fibrin plates, they showed similar fibrinolytic activity, but the t-PA calibration curve was not parallel to those obtained with UK and scu-PA. Relative thrombolytic and fibrinogenolytic properties were studied for each thrombolytic agent. For similar thrombolytic activities, fibrinogenolysis provoked by scu-PA was less marked than with t-PA and with both UK, while SK showed the highest activity. Our results demonstrate that the thrombolytic/fibrinogenolytic ratio is much more favorable to t-PA and scu-PA than to both forms of UK. Another observation clearly shows that fibrinogenolysis can be induced in vitro in human plasma by high doses of t-PA. This consequence may be important since the therapeutic use of t-PA can be associated with high concentrations of t-PA, and thus t-PA infusion could lead in vivo to severe fibrinogen breakdown. In addition, the methodology described could be useful in standardizing comparison between different species of thrombolytic agents.
Similar articles
-
[New thrombolytic agents].Ann Biol Clin (Paris). 1987;45(2):212-8. Ann Biol Clin (Paris). 1987. PMID: 3113300 French.
-
[New thrombolytic agents in myocardial infarction].Arch Mal Coeur Vaiss. 1987 Nov;80(12):1785-91. Arch Mal Coeur Vaiss. 1987. PMID: 3128222 Review. French.
-
Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.Biochemistry (Mosc). 2003 Nov;68(11):1252-60. doi: 10.1023/b:biry.0000009141.17272.6c. Biochemistry (Mosc). 2003. PMID: 14640969
-
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.Thromb Haemost. 1986 Aug 20;56(1):35-9. Thromb Haemost. 1986. PMID: 3095946
-
Pharmacology of thrombolytic drugs.J Am Coll Cardiol. 1986 Dec;8(6 Suppl B):33B-40B. doi: 10.1016/s0735-1097(86)80005-5. J Am Coll Cardiol. 1986. PMID: 3097100 Review.
Cited by
-
Thrombus composition and thrombolysis resistance in stroke.Res Pract Thromb Haemost. 2023 May 16;7(4):100178. doi: 10.1016/j.rpth.2023.100178. eCollection 2023 May. Res Pract Thromb Haemost. 2023. PMID: 37538503 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources